Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Blood Flow Restriction & Tennis Elbow Rehab

NCT: NCT05237869 · SUSPENDED

NCT IDNCT05237869
StatusSUSPENDED
Start Date2022-05-20
Completion2027-04
SponsorJulie Nuelle (OTHER)
First posted
Last updated

Brief Summary

Lateral epicondylitis (LE), often referred to as "tennis elbow" is a common and debilitating overuse injury affecting 1-3% of adults annually. LE is most often defined as a syndrome of pain near the area of the lateral epicondyle of the elbow commonly effecting the origin of the extensor carpi radialis brevis with associated weakness; it most commonly effects the dominant arm. The best treatment for LE is unknown and research to support current treatment methods are insufficient. A common limitation in functional recovery experienced by this population is pain at the lateral aspect of the elbow. As such, innovative therapeutic interventions directed at quickly reducing pain may address this unmet need and allow for improved outcomes, as well as earlier return to function.

Frequently Asked Questions

What is Blood Flow Restriction & Tennis Elbow Rehab?

Blood Flow Restriction & Tennis Elbow Rehab is a clinical trial registered under NCT05237869. Current status: SUSPENDED.

What is the status of NCT05237869?

The current status of NCT05237869 (Blood Flow Restriction & Tennis Elbow Rehab) is: SUSPENDED.

When did Blood Flow Restriction & Tennis Elbow Rehab start?

Blood Flow Restriction & Tennis Elbow Rehab started on 2022-05-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.